Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18977144 | NOVEL ANTIGEN BINDING MOLECULE FORMATS | December 2024 | April 2025 | Allow | 4 | 1 | 0 | No | No |
| 18664070 | BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLS | May 2024 | March 2025 | Allow | 10 | 2 | 0 | No | No |
| 18664091 | BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLS | May 2024 | December 2024 | Allow | 7 | 1 | 0 | No | No |
| 18640981 | NOVEL ANTIGEN BINDING MOLECULE FORMATS | April 2024 | February 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18408386 | NUCLEIC ACIDS, VECTORS, AND CELLS THAT ENCODE ANTI-SP17 ANTIBODIES AND OTHER SP17 BINDING PROTEINS | January 2024 | October 2024 | Allow | 9 | 3 | 0 | No | No |
| 18395074 | IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF | December 2023 | April 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18494454 | VARIANT IgG FC POLYPEPTIDES AND USES THEREOF | October 2023 | March 2024 | Allow | 4 | 0 | 1 | No | No |
| 18376135 | NANOEMULSION COMPOSITIONS FOR PREVENTING, SUPPRESSING OR ELIMINATING ALLERGIC AND INFLAMMATORY DISEASE | October 2023 | May 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18469961 | HLA BINDING VACCINE MOIETIES AND USES THEREOF | September 2023 | March 2025 | Allow | 18 | 2 | 0 | No | No |
| 18469947 | NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND BCMA VARIANTS WITH FC-ENGINEERING | September 2023 | August 2024 | Allow | 11 | 1 | 1 | No | No |
| 18462987 | SOYBEAN ALLERGY ANTIGEN | September 2023 | June 2025 | Allow | 21 | 2 | 1 | No | No |
| 18331280 | Antibodies that Specifically Bind PD-1 and Methods of Use | June 2023 | November 2024 | Allow | 18 | 1 | 0 | No | No |
| 18318871 | NOVEL ANTIGEN BINDING MOLECULE FORMATS | May 2023 | December 2023 | Allow | 7 | 1 | 0 | No | No |
| 18308338 | IL-21 POLYPEPTIDES AND TARGETED CONSTRUCTS | April 2023 | December 2024 | Allow | 20 | 2 | 2 | Yes | No |
| 18303769 | CHIMERIC CANINE ANTI-CD20 ANTIBODY | April 2023 | September 2024 | Allow | 17 | 2 | 0 | No | No |
| 18164442 | AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE | February 2023 | June 2023 | Allow | 5 | 0 | 0 | No | No |
| 18160745 | Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor | January 2023 | November 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18018444 | IL23 RECEPTOR SYNTHETIC CYTOKINES AND METHODS OF USE | January 2023 | April 2025 | Abandon | 26 | 3 | 1 | No | No |
| 18101601 | PD1-CD70 FUSION PROTEIN AND METHODS OF USE THEREOF | January 2023 | December 2024 | Abandon | 23 | 0 | 1 | No | No |
| 18006484 | IFNGR BINDING SYNTHETIC CYTOKINES AND METHODS OF USE | January 2023 | June 2024 | Allow | 16 | 2 | 1 | No | No |
| 18067504 | CD33-Binding Polypeptides and Uses Thereof | December 2022 | May 2024 | Allow | 17 | 0 | 0 | No | No |
| 18063896 | METHOD OF INDUCING TOLERANCE TO AN ALLERGEN | December 2022 | May 2025 | Abandon | 29 | 2 | 0 | No | No |
| 17980397 | COMBINATIONS FOR ALLERGY THERAPY | November 2022 | February 2024 | Abandon | 16 | 2 | 1 | No | No |
| 18050993 | Therapeutic Anti-IgE Antibodies and Methods and Compositions Thereof | October 2022 | April 2025 | Abandon | 29 | 0 | 1 | No | No |
| 17921355 | PREPARATION AND APPLICATION OF AN INTACT RECOMBINANT ANTIBODY SPECIFIC TO CLOTHIANIDIN BASED ON THE IDENTIFIED VARIABLE REGION SEQUENCE | October 2022 | November 2023 | Allow | 13 | 2 | 0 | No | No |
| 17945504 | Immunotherapy For The Treatment Of Allergic Disease | September 2022 | September 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17891757 | MIXED ALLERGEN COMPOSITIONS AND METHODS FOR USING THE SAME | August 2022 | April 2025 | Allow | 32 | 2 | 0 | Yes | No |
| 17887144 | BETA-GLUCAN IMMUNOTHERAPIES AFFECTING THE IMMUNE MICROENVIRONMENT | August 2022 | September 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17877432 | ANTIBODIES THAT BIND HUMAN CANNABINOID 1 (CB1) RECEPTOR | July 2022 | May 2025 | Abandon | 34 | 2 | 0 | Yes | No |
| 17858112 | PROCESS FOR OBTAINING ANTIBODIES | July 2022 | December 2024 | Allow | 29 | 2 | 0 | No | No |
| 17848808 | FC VARIANTS WITH REDUCED EFFECTOR FUNCTION | June 2022 | October 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17834237 | Anti-PD-1 Antibodies and Uses Thereof | June 2022 | October 2023 | Allow | 16 | 0 | 0 | Yes | No |
| 17752639 | METHODS OF ORAL IMMUNOTHERAPY | May 2022 | May 2025 | Allow | 35 | 2 | 1 | Yes | No |
| 17736859 | METHODS OF TREATING AN ALLERGY WITH ALLERGEN-SPECIFIC MONOCLONAL ANTIBODIES | May 2022 | March 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17714507 | ANTI-ALLERGEN ANTIBODIES | April 2022 | January 2025 | Allow | 34 | 1 | 0 | No | No |
| 17707243 | RECOMBINANT INTRAVENOUS IMMUNOGLOBULIN (RIVIG) COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND USE | March 2022 | June 2023 | Allow | 15 | 0 | 0 | Yes | No |
| 17672571 | NOVEL IMMUNOTHERAPEUTIC COMPOSITION AND USES THEREOF | February 2022 | January 2024 | Allow | 23 | 0 | 0 | Yes | No |
| 17648242 | METHODS OF TREATING KAWASAKI DISEASE | January 2022 | May 2024 | Allow | 28 | 1 | 0 | No | No |
| 17510772 | PEANUT HYPOALLERGENIC FORMULATIONS FOR DETERMINING THE RISK OF ANAPHYLAXIS | October 2021 | May 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17501305 | IMMUNE MODULATION | October 2021 | August 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17500418 | HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF | October 2021 | November 2024 | Allow | 37 | 1 | 1 | No | No |
| 17500794 | ANTIBODIES TO OXIDATION-SPECIFIC EPITOPES | October 2021 | March 2025 | Allow | 41 | 2 | 0 | Yes | No |
| 17498512 | TREATMENT OF CANCER USING A CEA CD3 BISPECIFIC ANTIBODY AND A WNT SIGNALING INHIBITOR | October 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17601628 | COMBINATION OF SYNTHETIC PEPTIDES WITH AFFINITY TO THE TGF-� RECEPTOR AND WITH AFFINITY TO THE IL-10 RECEPTOR, PHARMACEUTICAL COMPOSITION AND THEIR USE AS IMMUNOMODULATORS IN THE TREATMENT OF AUTOIMMUNE, INFLAMMATORY OR ALLERGIC DISEASES | October 2021 | June 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17601359 | METHODS OF DEPLETING DISEASE CAUSING AGENTS VIA ANTIBODY TARGETED PHAGOCYTOSIS | October 2021 | December 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17438702 | Manufacturing Methods for Producing Anti-TNF Antibody Compositions | September 2021 | February 2024 | Allow | 29 | 1 | 0 | No | No |
| 17471804 | ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF | September 2021 | December 2023 | Allow | 27 | 1 | 0 | No | No |
| 17438209 | NON-CONSENSUS GLYCOSYLATION OF BISPECIFIC ANTIBODIES | September 2021 | November 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17432705 | MODIFIED FC FRAGMENT, ANTIBODY COMPRISING SAME, AND APPLICATION THEREOF | August 2021 | February 2025 | Allow | 42 | 5 | 1 | Yes | No |
| 17399871 | CONDITIONING REGIMENS AND METHODS FOR INDUCING MIXED CHIMERISM | August 2021 | January 2024 | Allow | 29 | 2 | 0 | No | No |
| 17384628 | MIXED ALLERGEN COMPOSITIONS AND METHODS FOR USING THE SAME | July 2021 | January 2025 | Abandon | 42 | 2 | 1 | Yes | No |
| 17374519 | NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF | July 2021 | December 2023 | Allow | 29 | 1 | 0 | No | No |
| 17368366 | NANOEMULSION COMPOSITIONS FOR PREVENTING, SUPPRESSING OR ELIMINATING ALLERGIC AND INFLAMMATORY DISEASE | July 2021 | June 2023 | Allow | 24 | 1 | 0 | No | No |
| 17364299 | METHODS OF TREATING ALLERGY USING ANTI-BET V 1 ANTIBODIES | June 2021 | September 2023 | Allow | 27 | 2 | 0 | No | No |
| 17414265 | ANTIGEN BINDING FORMATS FOR RECEPTOR COMPLEXES | June 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17298104 | METHODS FOR MAKING MIXED ALLERGEN COMPOSITIONS | May 2021 | September 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17297796 | ANTIBODY COMPRISING A GLUTAMINE-CONTAINING LIGHT CHAIN C-TERMINAL EXTENSION, CONJUGATES THEREOF, AND METHODS AND USES | May 2021 | December 2024 | Allow | 43 | 1 | 0 | No | No |
| 17303268 | METHODS OF TREATING INFLAMMATORY DISEASES BY BLOCKING GALECTIN-3 | May 2021 | December 2024 | Allow | 43 | 4 | 1 | Yes | No |
| 17325268 | MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND USES THEREOF | May 2021 | December 2023 | Allow | 31 | 0 | 1 | No | No |
| 17315547 | VARIABLE REGIONS FOR NKP46 BINDING PROTEINS | May 2021 | September 2023 | Allow | 29 | 0 | 1 | Yes | No |
| 17243372 | ANTI-PD-L1 ANTIBODIES | April 2021 | September 2024 | Allow | 40 | 2 | 1 | No | No |
| 17285884 | RAPID CELL ISOLATION AND RECOVERY USING HOLLOW GLASS MICROSPHERES COATED WITH BIODEGRADABLE NANOSTRUCTURED FILMS | April 2021 | June 2025 | Allow | 50 | 2 | 1 | No | No |
| 17231544 | MIXED ALLERGEN COMPOSITIONS AND METHODS FOR USING THE SAME | April 2021 | January 2025 | Abandon | 45 | 2 | 1 | Yes | No |
| 17282781 | HER2-BINDING TETRAMERIC POLYPEPTIDES | April 2021 | June 2025 | Abandon | 50 | 0 | 1 | No | No |
| 17279958 | METHODS FOR DETECTING HOOK EFFECT(S) ASSOCIATED WITH ANAYLTE(S) OF INTEREST DURING OR RESULTING FROM THE CONDUCTANCE OF DIAGNOSTIC ASSAY(S) | March 2021 | February 2025 | Allow | 47 | 1 | 0 | No | No |
| 17278164 | ANTI-IgE ANTIBODY SPECIFICALLY BINDING TO MEMBRANE-BOUND IgE ANTIBODY OF IgE ANTIBODY-PRODUCING B CELLS AND METHOD FOR DIAGNOSING AND TREATING ALLERGIC SYMPTOMS USING THE SAME | March 2021 | January 2025 | Allow | 46 | 1 | 1 | No | No |
| 17200374 | NOVEL ANTI-PD-L1 ANTIBODIES | March 2021 | August 2024 | Allow | 41 | 2 | 1 | Yes | No |
| 17147699 | METHOD AND MEANS FOR DIAGNOSING AND TREATING ALLERGY | January 2021 | March 2024 | Allow | 38 | 2 | 0 | Yes | Yes |
| 17259271 | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CTLA-4 | January 2021 | September 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17259067 | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO PD-L1 | January 2021 | September 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17142825 | DIAGNOSTIC TESTS AND METHODS FOR ASSESSING SAFETY, EFFICACY OR OUTCOME OF ALLERGEN-SPECIFIC IMMUNOTHERAPY (SIT) | January 2021 | February 2024 | Abandon | 38 | 2 | 0 | No | No |
| 17127688 | ANTI-C5a RECEPTOR ANTIBODIES | December 2020 | February 2024 | Abandon | 38 | 2 | 1 | No | No |
| 17056460 | Biomarkers for improving nutrion for infants at risk | November 2020 | September 2024 | Abandon | 46 | 1 | 0 | No | No |
| 17053784 | LAMP CONSTRUCTS COMPRISING ALLERGENS | November 2020 | January 2025 | Allow | 51 | 3 | 1 | Yes | No |
| 17070129 | Anti-CTLA-4 Antibodies and Uses Thereof | October 2020 | February 2024 | Allow | 40 | 2 | 0 | Yes | No |
| 16980607 | METABOLIC ENZYME ACTIVITY AND DISULFIDE BOND REDUCTION DURING PROTEIN PRODUCTION | September 2020 | February 2025 | Allow | 53 | 2 | 1 | No | No |
| 16987487 | NOVEL ANTIGEN BINDING MOLECULE FORMATS | August 2020 | September 2024 | Allow | 49 | 1 | 1 | Yes | No |
| 16984946 | ANTI-KIT ANTIBODIES AND USES THEREOF | August 2020 | September 2023 | Allow | 37 | 1 | 1 | No | No |
| 16961418 | Modified Cell Expansion and Uses Thereof | July 2020 | November 2024 | Abandon | 52 | 1 | 1 | No | No |
| 16958072 | ANTIBODIES AND ASSAYS FOR CCL14 | June 2020 | September 2023 | Allow | 39 | 1 | 1 | Yes | No |
| 16902518 | A B Cell Depleting Agent for the Treatment of Atherosclerosis | June 2020 | March 2024 | Allow | 45 | 5 | 0 | No | No |
| 16770467 | MULTISPECIFIC MOLECULES AND USES THEREOF | June 2020 | March 2025 | Abandon | 58 | 3 | 1 | Yes | No |
| 16842675 | PEANUT FORMULATIONS AND USES THEREOF | April 2020 | February 2024 | Allow | 46 | 4 | 0 | Yes | No |
| 16646279 | IDENTIFICATION AND MONITORING OF IMMUNOGLOBULIN J CHAINS | March 2020 | June 2023 | Allow | 40 | 2 | 0 | No | No |
| 16611859 | METHODS OF PURIFYING ANTIBODIES | November 2019 | March 2024 | Allow | 52 | 2 | 1 | Yes | No |
| 16664849 | METHODS OF POPULATING PRECIPITATED PARTICLES OF A MODIFIED OR SYNTHESIZED SUBSTANCE IN A TISSUE | October 2019 | April 2024 | Abandon | 53 | 2 | 1 | No | Yes |
| 16608239 | ALLERGY ANTIGEN AND EPITOPE THEREOF | October 2019 | January 2024 | Abandon | 51 | 2 | 2 | No | No |
| 16606656 | METHOD OF PREPARING pH-DEPENDENT ANTIBODIES | October 2019 | March 2024 | Allow | 53 | 2 | 1 | No | No |
| 16495552 | METHODS AND COMPOSITIONS FOR INDUCIBLE EXTRACELLULAR MEMBRANE CAPTURE OF MONOCLONAL IMMUNOGLOBULINS SECRETED BY HYBRIDOMAS | September 2019 | December 2023 | Allow | 51 | 2 | 1 | No | No |
| 16542198 | PEANUT ORAL IMMUNOTHERAPY WITH MAINTENANCE DOSE | August 2019 | June 2025 | Allow | 60 | 7 | 1 | No | No |
| 16428411 | DIFFERENTIAL DIAGNOSIS OF ECZEMA AND PSORIASIS | May 2019 | February 2024 | Allow | 57 | 4 | 1 | No | No |
| 16417946 | Peptides And Methods For Detecting Peanut Allergies | May 2019 | June 2025 | Abandon | 60 | 4 | 2 | No | No |
| 16349965 | BISPECIFIC OR BIPARATOPIC ANTIGEN BINDING PROTEINS AND USES THEREOF | May 2019 | October 2024 | Abandon | 60 | 1 | 1 | No | No |
| 16343162 | ADAPTER CHIMERIC ANTIGEN RECEPTOR EXPRESSING CELLS FOR TARGETING OF MULTIPLE ANTIGENS | April 2019 | November 2023 | Abandon | 55 | 2 | 1 | No | No |
| 16335022 | POLYPEPTIDE CONSTRUCT COMPRISING FRAGMENTS OF ALLERGENS | March 2019 | September 2023 | Allow | 54 | 3 | 1 | Yes | No |
| 16325144 | ANTI-PD-1 ANTIBODY | February 2019 | November 2024 | Abandon | 60 | 9 | 0 | Yes | Yes |
| 16311434 | ANTI-PD-L1 AND IL-2 CYTOKINES | December 2018 | May 2023 | Allow | 52 | 2 | 1 | Yes | Yes |
| 16309453 | FISH ALLERGY ANTIGEN | December 2018 | February 2024 | Abandon | 60 | 5 | 1 | Yes | No |
| 16081032 | SOYBEAN ALLERGY ANTIGEN | August 2018 | December 2023 | Abandon | 60 | 5 | 1 | Yes | No |
| 15682247 | Methods Of Using Chimeric Receptors To Identify Autoimmune Disease | August 2017 | April 2018 | Allow | 7 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ROONEY, NORA MAUREEN.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 40.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner ROONEY, NORA MAUREEN works in Art Unit 1641 and has examined 206 patent applications in our dataset. With an allowance rate of 80.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 39 months.
Examiner ROONEY, NORA MAUREEN's allowance rate of 80.1% places them in the 43% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by ROONEY, NORA MAUREEN receive 2.45 office actions before reaching final disposition. This places the examiner in the 84% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by ROONEY, NORA MAUREEN is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +17.0% benefit to allowance rate for applications examined by ROONEY, NORA MAUREEN. This interview benefit is in the 62% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 23.8% of applications are subsequently allowed. This success rate is in the 24% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 47.6% of cases where such amendments are filed. This entry rate is in the 67% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 86.7% of appeals filed. This is in the 77% percentile among all examiners. Of these withdrawals, 76.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 55.6% are granted (fully or in part). This grant rate is in the 70% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 7.3% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.6% of allowed cases (in the 74% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.